IPP Bureau
Hyderabad startup’s Physiotherapy monitoring device ‘Pheezee’ receives USFDA
By IPP Bureau - May 05, 2023
Pheezee is designed to assess musculoskeletal and neuromuscular health.
PredOmix launches campaign for free cancer screening
By IPP Bureau - May 05, 2023
PredOmix has developed a novel blood test that can detect about 32 cancers in both men and women with 98 percent accuracy
Nouscom reaches clinical phase II using ProBioGen’s AGE1.CR.pIX production platform
By IPP Bureau - May 05, 2023
Nous-209 has been developed using the Nouscom's viral vector platform
Brain Cells are starved of energy when autophagy malfunctions: New Study
By IPP Bureau - May 05, 2023
The Research by Indian Fellow at the University has major implications for neurodegenerative disease treatments
Merck plans bioprocessing center in South Korea
By IPP Bureau - May 05, 2023
The planned bioprocessing facility would support commercial manufacturing for biotech and pharmaceutical customers across Asia-Pacific.
IMCD becomes new distributor for Evonik’s medical care polymer materials
By IPP Bureau - May 04, 2023
New agreement applies to the polymers of the Medical Care series portfolio
Strides and Orbicular enter into a strategic partnership to develop a range of nasal sprays
By IPP Bureau - May 04, 2023
The partnership will commercialize four nasal sprays with a combined Global IQVIA market size in excess of $400m
AstraZeneca Pharma India receives permission for sale and distribution of Trastuzumab deruxtecan
By IPP Bureau - May 04, 2023
The receipt of this permission paves way for the launch of Trastuzumab deruxtecan (Enhertu) solution of 100mg/5mL in India
Indoco receives EIR for its Plant I manufacturing facility in Goa
By IPP Bureau - May 04, 2023
Indoco expects this change in compliance status to pave the way for approvals of ANDAs submitted from this site.
USFDA puts on hold Sun Pharma trials on dermatological drug
By IPP Bureau - May 04, 2023
Sun Pharma said had a teleconference call with the US Food and Drug Administration (USFDA) regarding a pulmonary embolism (serious adverse events) occurring at the 12 mg dose
Mandaviya reviews organ donation policy
By IPP Bureau - May 04, 2023
Organ Transplants triple across the country; rise from 5000 (2013) to more than 15000 in 2022
Astec LifeSciences appoints K. Suryanarayan as Chief Financial Officer
By IPP Bureau - May 04, 2023
He has over two decades of leadership experience as an innovative strategic planner in finance diligence
Astec LifeSciences FY23 PAT declines to Rs. 25.6 Cr
By IPP Bureau - May 03, 2023
The consolidated EBITDA stood at Rs. 89.3 crore in FY23 as compared to Rs. 164.5 crore in the same period last year
Laurus Labs receives USFDA tentative approval for Dolutegravir 5mg and 10mg in HIV/AIDS treatment
By IPP Bureau - May 03, 2023
It will help in bringing a significant benefit in compliance of ARV medication in the paediatric HIV treatment
USFDA Advisory Committee votes n Lynparza plus Abiraterone and Prednisone for prostate cancer
By IPP Bureau - May 03, 2023
The committee voted that FDA should restrict use of LYNPARZA plus abi/pred to these BRCAm mCRPC patients
